Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Antisense and RNAi therapeutics Market, by region, 2020-2030 (USD Billion)
1.2.2. Antisense and RNAi therapeutics Market, by Technology, 2020-2030 (USD Billion)
1.2.3. Antisense and RNAi therapeutics Market, by Application, 2020-2030 (USD Billion)
1.2.4. Antisense and RNAi therapeutics Market, by Route of Administration, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Antisense and RNAi therapeutics Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Antisense and RNAi therapeutics Market Dynamics
3.1. Antisense and RNAi therapeutics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing incidences of genetic disorders
3.1.1.2. Growing pipeline of antisense and RNAi drugs
3.1.1.3. Increasing investment and funding for therapeutics development
3.1.2. Market Challenges
3.1.2.1. High Cost of Antisense and RNAi therapeutics
3.1.3. Market Opportunities
3.1.3.1. Rising development of personalized medicine
3.1.3.2. Increased collaboration and partnerships
Chapter 4. Global Antisense and RNAi therapeutics Market: Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economic
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Antisense and RNAi therapeutics Market, by Technology
5.1. Market Snapshot
5.2. Global Antisense and RNAi therapeutics Market by Technology, Performance - Potential Analysis
5.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
5.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
5.4.1. RNA Interference
5.4.2. Antisense RNA
Chapter 6. Global Antisense and RNAi therapeutics Market, by Application
6.1. Market Snapshot
6.2. Global Antisense and RNAi therapeutics Market by Application, Performance - Potential Analysis
6.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
6.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
6.4.1. Genetic Disease
6.4.2. Cancer
6.4.3. Infectious Disease
6.4.4. Neurodegenerative Disorders
6.4.5. Cardiometabolic & Renal Disorders
6.4.6. Ocular Disorders
6.4.7. Respiratory Disorders
6.4.8. Skin Disorders
Chapter 7. Global Antisense and RNAi therapeutics Market, by Route of Administration
7.1. Market Snapshot
7.2. Global Antisense and RNAi therapeutics Market by Route of Administration, Performance - Potential Analysis
7.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
7.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
7.4.1. Intravenous Injections
7.4.2. Intrathecal Injections
7.4.3. Subcutaneous Injections
7.4.4. Other Delivery Methods
Chapter 8. Global Antisense and RNAi therapeutics Market, Regional Analysis
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Antisense and RNAi therapeutics Market, Regional Market Snapshot
8.4. North America Antisense and RNAi therapeutics Market
8.4.1. U.S. Antisense and RNAi therapeutics Market
8.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
8.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Antisense and RNAi therapeutics Market
8.5. Europe Antisense and RNAi therapeutics Market Snapshot
8.5.1. U.K. Antisense and RNAi therapeutics Market
8.5.2. Germany Antisense and RNAi therapeutics Market
8.5.3. France Antisense and RNAi therapeutics Market
8.5.4. Spain Antisense and RNAi therapeutics Market
8.5.5. Italy Antisense and RNAi therapeutics Market
8.5.6. Rest of Europe Antisense and RNAi therapeutics Market
8.6. Asia-Pacific Antisense and RNAi therapeutics Market Snapshot
8.6.1. China Antisense and RNAi therapeutics Market
8.6.2. India Antisense and RNAi therapeutics Market
8.6.3. Japan Antisense and RNAi therapeutics Market
8.6.4. Australia Antisense and RNAi therapeutics Market
8.6.5. South Korea Antisense and RNAi therapeutics Market
8.6.6. Rest of Asia Pacific Antisense and RNAi therapeutics Market
8.7. Latin America Antisense and RNAi therapeutics Market Snapshot
8.7.1. Brazil Antisense and RNAi therapeutics Market
8.7.2. Mexico Antisense and RNAi therapeutics Market
8.8. Middle East & Africa Antisense and RNAi therapeutics Market
8.8.1. Saudi Arabia Antisense and RNAi therapeutics Market
8.8.2. South Africa Antisense and RNAi therapeutics Market
8.8.3. Rest of Middle East & Africa Antisense and RNAi therapeutics Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. GSK plc
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Olix Pharmaceuticals, Inc.
9.3.3. Sanofi S.A
9.3.4. Alnylam Pharmaceuticals, Inc.
9.3.5. Arbutus Biopharma
9.3.6. Benitec Biopharma Inc.
9.3.7. Silence Therapeutics
9.3.8. Ionis Pharmaceuticals, Inc
9.3.9. Sarepta Therapeutics
9.3.10. Percheron Therapeutics Limited
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption